Head-To-Head Survey: Pluri (NASDAQ:PLUR) & Entrada Therapeutics (NASDAQ:TRDA)
by Danessa Lincoln · The Markets DailyEntrada Therapeutics (NASDAQ:TRDA – Get Free Report) and Pluri (NASDAQ:PLUR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.
Risk and Volatility
Entrada Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.
Valuation and Earnings
This table compares Entrada Therapeutics and Pluri”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Entrada Therapeutics | $4.69 million | 56.50 | -$143.75 million | ($3.96) | -1.72 |
| Pluri | $1.02 million | 12.94 | -$22.58 million | ($4.53) | -0.26 |
Pluri has lower revenue, but higher earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and target prices for Entrada Therapeutics and Pluri, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Entrada Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
Entrada Therapeutics currently has a consensus price target of $17.75, indicating a potential upside of 161.03%. Given Entrada Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Entrada Therapeutics is more favorable than Pluri.
Institutional & Insider Ownership
86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Entrada Therapeutics and Pluri’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Entrada Therapeutics | -3,537.73% | -57.61% | -46.54% |
| Pluri | -2,162.08% | N/A | -106.59% |
Summary
Entrada Therapeutics beats Pluri on 8 of the 14 factors compared between the two stocks.
About Entrada Therapeutics
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
About Pluri
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.